Leerink Partnrs Issues Optimistic Estimate for ISRG Earnings

Key Points

• Leerink Partners has raised its FY2025 earnings per share estimate for Intuitive Surgical to $6.58, slightly higher than the previous estimate of $6.56 and surpassing the consensus estimate of $6.43.
• Several analysts have increased their price targets for Intuitive Surgical, with Truist Financial setting a new price objective of $600.00, while Piper Sandler raised theirs to $595.00.
• Despite recent insider selling, institutional ownership remains strong, with 83.64% of the company's stock held by institutional investors and hedge funds.

Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) - Equities research analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of Intuitive Surgical in a research report issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now forecasts that the medical equipment provider will post earnings per share of $6.58 for the year, up from their prior estimate of $6.56. The consensus estimate for Intuitive Surgical's current full-year earnings is $6.43 per share.

ISRG has been the topic of several other reports. Truist Financial increased their price objective on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Erste Group Bank reissued a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Piper Sandler reissued an "overweight" rating and issued a $595.00 price objective (up from $575.00) on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Royal Bank Of Canada restated an "outperform" rating and issued a $615.00 price target on shares of Intuitive Surgical in a research note on Tuesday, August 19th. Finally, Mizuho reduced their price target on Intuitive Surgical from $570.00 to $520.00 and set a "neutral" rating for the company in a research note on Tuesday. Fourteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $585.71.

Intuitive Surgical Stock Up 0.2%

NASDAQ:ISRG opened at $436.39 on Wednesday. The firm has a market capitalization of $156.44 billion, a price-to-earnings ratio of 60.86, a price-to-earnings-growth ratio of 4.58 and a beta of 1.61. The stock's 50 day moving average price is $456.92 and its two-hundred day moving average price is $497.02. Intuitive Surgical has a twelve month low of $425.00 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The business had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. During the same quarter last year, the firm earned $1.78 EPS. Intuitive Surgical's revenue for the quarter was up 21.4% compared to the same quarter last year.

Insider Buying and Selling

In related news, insider Gary S. Guthart sold 29,360 shares of the company's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the completion of the sale, the insider directly owned 19,827 shares in the company, valued at $9,368,059.23. This represents a 59.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Amy L. Ladd sold 335 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $440.69, for a total value of $147,631.15. Following the sale, the director owned 739 shares of the company's stock, valued at approximately $325,669.91. This represents a 31.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,224 shares of company stock worth $21,716,492 in the last ninety days. 0.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in Intuitive Surgical by 24.9% during the 4th quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider's stock worth $1,916,000 after buying an additional 731 shares during the period. GAMMA Investing LLC increased its stake in shares of Intuitive Surgical by 9.3% in the first quarter. GAMMA Investing LLC now owns 6,115 shares of the medical equipment provider's stock valued at $3,029,000 after buying an additional 518 shares during the period. Elevation Point Wealth Partners LLC increased its stake in shares of Intuitive Surgical by 16.1% in the first quarter. Elevation Point Wealth Partners LLC now owns 562 shares of the medical equipment provider's stock valued at $278,000 after buying an additional 78 shares during the period. 1900 Wealth Management LLC increased its stake in shares of Intuitive Surgical by 21.2% in the first quarter. 1900 Wealth Management LLC now owns 475 shares of the medical equipment provider's stock valued at $235,000 after buying an additional 83 shares during the period. Finally, Sowell Financial Services LLC acquired a new stake in shares of Intuitive Surgical in the first quarter valued at about $2,270,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.